In a patient with intracerebral hemorrhage and an elevated international normalized ratio (INR), what is the role of fresh frozen plasma (FFP) in management?

FFP is a Second-Line Agent for INR Reversal in Warfarin-Associated ICH

Prothrombin complex concentrate (PCC) is superior to fresh frozen plasma (FFP) for reversing elevated INR in patients with intracerebral hemorrhage, and FFP should only be used when PCC is unavailable or as adjunctive therapy if INR remains elevated after PCC administration. 1

Primary Reversal Strategy

For warfarin-associated ICH with INR ≥1.4:

• First-line: 4-factor PCC (25-50 IU/kg based on INR and weight) plus vitamin K 10 mg IV 1, 2
• PCC achieves INR normalization significantly faster than FFP (within 4.8 hours vs 7.3 hours) 3
• The landmark INCH trial demonstrated that 67% of PCC-treated patients achieved INR ≤1.2 within 3 hours compared to only 9% with FFP 4

Critical point: Always administer vitamin K (5-10 mg IV) regardless of whether you use PCC or FFP, as PCC alone can cause INR rebound at 12-24 hours, potentially leading to hematoma expansion 1

When FFP Has a Role

FFP should be used in these specific scenarios:

1. PCC unavailable or contraindicated: Use FFP 10-15 mL/kg IV plus vitamin K 10 mg IV 2
2. Persistent INR elevation: If INR remains ≥1.4 at 24-48 hours after initial PCC dosing, add FFP for further correction 2
3. Combined therapy: Some evidence suggests FFP + PCC together may yield the lowest mortality (27.8% vs 37.3% for PCC alone vs 45.6% for FFP alone), though this requires further validation 5

Clinical Outcomes Evidence

The superiority of PCC is based on both laboratory and clinical endpoints:

• Hematoma expansion: PCC reduces expansion incidence (19% vs 33% with FFP vs 50% with vitamin K alone) 6
• Mortality: The INCH trial showed 5 deaths from hematoma expansion in the FFP group (all within 48 hours) versus zero in the PCC group 4
• Symptom progression: Patients receiving PCC progressed 0.2 grades on clinical scales versus 1.9 grades with FFP 3

Dosing Specifics

For PCC:

• INR ≥2.0: 25-50 IU/kg (weight-based) or fixed 1500 IU for intracranial bleeding 1
• INR 1.3-1.9: Lower dose 10-20 IU/kg to minimize thrombotic risk 1

For FFP (when necessary):

• 10-15 mL/kg IV 2
• Requires significantly larger volume than PCC, which can be problematic in volume-sensitive patients 7

Monitoring Algorithm

1. Check INR 15-60 minutes after PCC administration 2
2. Recheck serially every 6-8 hours for 24-48 hours 2
3. If INR remains ≥1.4 after initial PCC, consider adding FFP 2
4. Target INR <1.3 (some sources suggest <1.2) 1, 2

Common Pitfalls

• Giving PCC without vitamin K: This can cause INR rebound and clinical deterioration 1
• Using FFP as first-line when PCC is available: This delays adequate reversal and may worsen outcomes 4
• Excessive PCC dosing: Doses >2000-3000 IU increase VTE risk 1
• Not rechecking INR: Failure to monitor can miss inadequate reversal or rebound 2

Bottom Line

The 2022 AHA/ASA guidelines and 2016 Neurocritical Care Society guidelines both establish PCC as the preferred agent based on faster INR correction and potentially better clinical outcomes. FFP functions as a backup option when PCC is unavailable or as rescue therapy for persistent coagulopathy after PCC administration.